Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Mesa
R A
RA
Tefferi
A
A
Li
C-Yang
CY
Steensma
D P
DP
D000208:Acute Disease; D000369:Aged, 80 and over; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D000077269:Lenalidomide; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics*; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D017354:Point Mutation; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013792:Thalidomide; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D000077269:Lenalidomide